Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | HRH1 | P35367 | 2/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20832578 | 0.82 | — | — | |
| SCHEMBL22725661 | 0.81 | TSHR (0.38) | CYP2D6KCNH2 | |
| SCHEMBL29332959 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL20756637 | 0.78 | ESR1 (0.36) | — | |
| SCHEMBL23661740 | 0.77 | ESR1 (0.37) | HRH4 | |
| SCHEMBL26396496 | 0.77 | CYP2D6 (0.32) | CYP2D6HRH1CHRM1KCNH2 | |
| SCHEMBL21653566 | 0.77 | SMN1; SMN2 (0.33) | CYP2D6KCNH2 | |
| SCHEMBL22725519 | 0.76 | — | — | |
| SCHEMBL19919582 | 0.76 | APLNR (0.36) | HRH4 | |
| SCHEMBL18559669 | 0.76 | NOS3 (0.35) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170151248-A1 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS | ELI LILLY AND COMPANY | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151248-A1 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS | TRPA1, TRPV1, TRPV2 | HRH4 367/4885CYP2D6 2910/4885HRH1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.